Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avanzini, P
Right arrow Articles by Vivoli, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avanzini, P
Right arrow Articles by Vivoli, G
Haematologica, Vol 80, Issue 6, 505-511
Copyright © 1995 by Ferrata Storti Foundation

Clinical Trial

Serum selenium concentrations in patients with newly diagnosed lymphoid malignancies

P Avanzini, M Vinceti, F Ilariucci, L Masini, M D'Inca, and G Vivoli

Divisione di Medicina Interna e Day-Hospital Ematologico, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.

BACKGROUND. Increased mortality from lymphoid malignancies following exposure to environmental selenium has recently been reported. Moreover, conflicting results have been found in investigations examining the relationship between serum concentrations of selenium and some clinical features of malignant lymphoproliferative diseases. METHODS. Serum concentrations of selenium were analyzed by atomic absorption spectrometry in fifty-nine patients with newly diagnosed chronic lymphoid malignancies and in forty control subjects. RESULTS. Selenium concentrations were significantly lower in patients than in control subjects. However, when only patients with localized disease were compared to controls, no significant difference in serum selenium concentrations was observed. Clinical stage was inversely associated with selenium levels. High-grade non-Hodgkin's lymphoma was characterized by lower selenium levels than low-grade and intermediate-grade disease. Selenium levels were positively associated with albumin and hemoglobin, and inversely correlated with serum concentrations of beta 2-microglobulin and with erythrocyte sedimentation rate. CONCLUSIONS. The findings of this study do not suggest that a high selenium intake represents a risk factor for malignant lymphoproliferative diseases, but limitations of the investigation hamper evaluation of the results. The possible utility of determining serum concentrations of selenium in the clinical evaluation of patients with lymphoid malignancies merits examination in larger studies.


This article has been cited by other articles:


Home page
 JCOHome page
Y. Beguin and G. Weber
Serum Selenium in Lymphoma
J. Clin. Oncol., August 15, 2004; 22(16): 3429 - 3429.
[Full Text] [PDF]

Home page
 JCOHome page
K. W. Last, V. Cornelius, T. Delves, C. Sieniawska, J. Fitzgibbon, A. Norton, J. Amess, A. Wilson, A. Z.S. Rohatiner, and T. A. Lister
Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol., June 15, 2003; 21(12): 2335 - 2341.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 1995 by the Ferrata Storti Foundation.